N-dithiocarboxy-glutamic acid | 75808-54-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-dithiocarboxy-glutamic acid
• 英文别名: N-Dithiocarboxy-glutaminsaeure；2-(Dithiocarboxyamino)pentanedioic acid
• CAS: 75808-54-7
• 化学式: C₆H₉NO₄S₂
• 分子量: 223.274
• InChiKey: SAOZKHJCFQSMFB-UHFFFAOYSA-N

物化性质

• 沸点：
  419.6±55.0 °C(Predicted)
• 密度：
  1.539±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  120
• 氢给体数：
  4
• 氢受体数：
  6

安全信息

• 海关编码：
  2930909090

反应信息

• 作为反应物：
  描述：

  N-dithiocarboxy-glutamic acid 在 sodium carbonate 、 溶剂黄146 、 β-丙氨酸 作用下， 生成
  参考文献：
  名称：

  Synthesis and evaluation of aryl thioxothiazolidinone inhibitors of ADAMTS-5 (Aggrecanase-2)

  摘要：

  5-Benzylidene-2-thioxo-thiazolidin-4-one inhibitors of ADAMTS-5 (Aggrecanase-2) have been prepared via commercially available starting materials. The identified compounds show micromolar ADAMTS-5 potency and demonstrate SAR trends for both the aryl group and thioxothiazolidinone zinc chelator. This series of compounds represents steps toward a metalloprotease inhibitor as a disease-modifying osteoarthritis drug. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.12.027
• 作为产物：
  描述：

  二硫化碳 、 DL-谷氨酸 在 氢氧化钾 作用下， 以 水 为溶剂， 生成 N-dithiocarboxy-glutamic acid
  参考文献：
  名称：

  Synthesis and evaluation of aryl thioxothiazolidinone inhibitors of ADAMTS-5 (Aggrecanase-2)

  摘要：

  5-Benzylidene-2-thioxo-thiazolidin-4-one inhibitors of ADAMTS-5 (Aggrecanase-2) have been prepared via commercially available starting materials. The identified compounds show micromolar ADAMTS-5 potency and demonstrate SAR trends for both the aryl group and thioxothiazolidinone zinc chelator. This series of compounds represents steps toward a metalloprotease inhibitor as a disease-modifying osteoarthritis drug. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.12.027

文献信息

• Pharmaceutical compositions and methods for treating anxiety, anxiety disorders and memory impairment using NAALADase inhibitors
  申请人：——

  公开号：US20030013687A1

  公开（公告）日：2003-01-16

  The present invention relates to pharmaceutical compositions and methods of using NAALADase inhibitors for treating glutamate-mediated diseases, disorders and conditions selected from the group consisting of anxiety, anxiety disorders and memory impairment.

  本发明涉及制药组合物及使用NAALADase抑制剂治疗由谷氨酸介导的疾病、疾病和病状的方法，所述疾病、疾病和病状包括焦虑、焦虑症和记忆障碍。
• Pharmaceutical compositions and methods of inhibiting angiogenesis using NAALADase inhibitors
  申请人：——

  公开号：US20030064912A1

  公开（公告）日：2003-04-03

  The present disclosure relates to a method of inhibiting angiogenesis comprising administering a N-Acetylated &agr;-Linked Acidic Dipeptidase (NAALADase) inhibitor to a patient in need thereof, and a pharmaceutical composition comprising an anti-angiogenic effective amount of a NAALADase inhibitor and a pharmaceutically acceptable carrier.

  本公开涉及一种抑制血管生成的方法，包括向需要该方法的患者给予N-乙酰化的α-连接酸性二肽酶（NAALADase）抑制剂，以及包含抗血管生成有效量的NAALADase抑制剂和药用载体的制药组合物。
• NAALADase inhibitors useful as pharmaceutical compounds and compositions
  申请人：——

  公开号：US20030083374A1

  公开（公告）日：2003-05-01

  The present invention relates to N-Acetylated &agr;-Linked Acidic Dipeptidase (NAALADase) inhibitors enzyme activity, pharmaceutical compositions comprising such inhibitors, and methods of their use to inhibit NAALADase enzyme activity, thereby effecting neuronal activities, inhibiting angiogenesis, and treating glutamate abnormalities, compulsive disorders, prostate diseases, pain and diabetic neuropathy.

  本发明涉及N-乙酰化的α-连接酸性二肽酶（NAALADase）抑制剂酶活性，包含这些抑制剂的制药组合物，以及使用它们抑制NAALADase酶活性的方法，从而影响神经活动，抑制血管生成，治疗谷氨酸异常、强迫性障碍、前列腺疾病、疼痛和糖尿病神经病变。
• Use of naaladase inhibitors for the manufacture of a medicament for the treatment of certain diseases
  申请人：GUILFORD PHARMACEUTICALS INC.

  公开号：EP1371367A1

  公开（公告）日：2003-12-17

  A method for regulating the release of TGF-β from living cells in vitro or in vivo, comprising bringing the cells into contact with an effective amount of a NAALADase inhibitor. Such methods are believed to useful for affecting neuroregeneration, cell proliferation, cell differentiation, extracellular matrix formation, myelination, inflammation, immune function, liver function, pancreatic function, angiogenesis, or wound healing; and/or preventing or treating diabetes.

  一种调节体外或体内活细胞释放 TGF-β 的方法，包括使细胞与有效量的 NAALAD 酶抑制剂接触。这种方法被认为有助于影响神经再生、细胞增殖、细胞分化、细胞外基质形成、髓鞘化、炎症、免疫功能、肝功能、胰腺功能、血管生成或伤口愈合；和/或预防或治疗糖尿病。
• Naaladase inhibitors useful as pharmaceutical compounds and compositions
  申请人：GUILFORD PHARMACEUTICALS INC.

  公开号：EP1571141A2

  公开（公告）日：2005-09-07

  The present invention relates to specific N-Acetylated α-Linked Acidic Dipeptidase (NAALADase) inhibitors, pharmaceutical compositions comprising these inhibitors, and their use for treating pain, prostate diseases, cancer, glutamate abnormality and diabetic neuropathy, as well as for inhibiting angiogenesis and effecting a neuronal activity.

  本发明涉及特异性N-乙酰化α-连接酸性二肽酶（NAALAD酶）抑制剂、包含这些抑制剂的药物组合物，以及它们在治疗疼痛、前列腺疾病、癌症、谷氨酸异常和糖尿病神经病变，以及抑制血管生成和影响神经元活性方面的用途。